These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 6621092)

  • 1. Heparin resistance during cardiopulmonary bypass.
    Hicks GL
    J Thorac Cardiovasc Surg; 1983 Oct; 86(4):633. PubMed ID: 6621092
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heparin resistance during cardiopulmonary bypass].
    Maeda R; Fukuda H; Nakaigawa Y; Hiruta M; Hirabayashi Y; Seo N
    Masui; 2003 Sep; 52(9):1003-5. PubMed ID: 14531265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 4. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?
    Rodríguez-López JM; del Barrio E; Lozano FS; Muriel C
    Anesth Analg; 2008 Oct; 107(4):1444-5. PubMed ID: 18806070
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-bonded cardiopulmonary bypass circuits reduce the rate of red blood cell transfusion during elective coronary artery bypass surgery.
    Kreisler KR; Vance RA; Cruzzavala J; Mahnken JD
    J Cardiothorac Vasc Anesth; 2005 Oct; 19(5):608-11. PubMed ID: 16202894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
    Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
    Jiang L; Yu JF
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin resistance.
    Bharadwaj J; Jayaraman C; Shrivastava R
    Lab Hematol; 2003; 9(3):125-31. PubMed ID: 14521318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin resistance after aprotinin.
    Fisher AR; Bailey CR; Shannon CN; Wielogorski AK
    Lancet; 1992 Nov; 340(8829):1230-1. PubMed ID: 1279335
    [No Abstract]   [Full Text] [Related]  

  • 14. Low molecular weight heparin: laboratory properties and clinical evaluation. A review.
    Hirsh J; Levine MN
    Eur J Surg Suppl; 1994; (571):9-22. PubMed ID: 7519092
    [No Abstract]   [Full Text] [Related]  

  • 15. Pro: heparin is the best anticoagulant for cardiopulmonary bypass.
    Rinder CS
    J Cardiothorac Vasc Anesth; 1996 Oct; 10(6):816-8. PubMed ID: 8910166
    [No Abstract]   [Full Text] [Related]  

  • 16. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
    J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass.
    Ovrum E
    Ann Thorac Surg; 1996 Mar; 61(3):1038-9. PubMed ID: 8619684
    [No Abstract]   [Full Text] [Related]  

  • 19. Heparin, cardiopulmonary bypass, and platelet dysfunction.
    Muriithi EW; Belcher PR
    Artif Organs; 2006 Jun; 30(6):488-9. PubMed ID: 16734602
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical relevance of preventing thrombosis with heparin and heparinoids].
    Zimmermann RE; Rogge H; Schwering H; Bünte H
    Med Welt; 1982 Mar; 33(11):408-9. PubMed ID: 6177998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.